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The over-expression and aggregation of α-synuclein (αSyn) are linked to the onset and pathology 
of Parkinson’s disease. Native monomeric αSyn exists in an intrinsically disordered ensemble of 
interconverting conformations, which has made its therapeutic targeting by small molecules highly 
challenging. Nonetheless, here we successfully target the monomeric structural ensemble of αSyn 
and thereby identify novel drug-like small molecules that impact multiple pathogenic processes. 
Using a surface plasmon resonance high-throughput screen, in which monomeric αSyn is incubated 
with microchips arrayed with tethered compounds, we identified novel αSyn interacting drug-like 
compounds. Because these small molecules could impact a variety of αSyn forms present in the 
ensemble, we tested representative hits for impact on multiple αSyn malfunctions in vitro and in cells 
including aggregation and perturbation of vesicular dynamics. We thereby identified a compound 
that inhibits αSyn misfolding and is neuroprotective, multiple compounds that restore phagocytosis 
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impaired by αSyn overexpression, and a compound blocking cellular transmission of αSyn. Our studies 
demonstrate that drug-like small molecules that interact with native αSyn can impact a variety of its 
pathological processes. Thus, targeting the intrinsically disordered ensemble of αSyn offers a unique 
approach to the development of small molecule research tools and therapeutics for Parkinson’s disease.
The sequential misfolding of α-synuclein (αSyn) into oligomers and fibrils is central to the pathogenesis of 
Parkinson’s Disease (PD) and related neurodegenerative disorders termed synucleinopathies1. Lewy bodies 
containing αSyn amyloid-like fibril inclusions are a hallmark neuropathological feature of these diseases2. The 
severity of disease correlates with the progressive spread of aggregated αSyn in patients3, and αSyn misfolding is 
associated with toxicity in cell and animal models4. In addition, strong genetic evidence links αSyn to PD includ-
ing gene multiplications or missense mutations that cause rare early onset forms of PD5–7 and genetic association 
studies also link αSyn to sporadic PD8,9. This combined neuropathological, biochemical and genetic evidence 
provides strong support implicating the misfolding and aggregation of αSyn as a key feature in PD.
Monomeric αSyn, as an intrinsically disordered protein (IDP), exists primarily as a dynamic ensemble of dis-
tinct interconverting conformations that have the ability to take on more structured forms under the appropriate 
cellular context10,11. In particular, αSyn can take on more ordered forms upon membrane binding12–14. Owing to 
this intrinsic dynamic character and the ability to populate other forms upon interaction, IDPs are involved in 
many key biological processes15, are vulnerable to aggregation and are susceptible to prion-like amplification of 
misfolded species and transmission between cells16. This propensity towards aggregation and spread is likely to 
underlie the association that IDPs have with a growing number of misfolding diseases, notably many neurode-
generative disorders17.
Small molecule binding to native states of globular proteins has been successfully used to block misfolding 
and aggregation18 most notably in the case of targeting transthyretin to treat systemic amyloidosis19. By con-
trast, targeting of IDPs such as native monomeric αSyn with small molecules has been challenging due to their 
inherent structural heterogeneity and the absence of persistent structural elements10. Yet, the dynamic nature of 
the monomeric form of αSyn also provides opportunity to impact multiple aspects of the protein. For example, 
small molecules interacting with native αSyn could protect and stabilize specific conformations present in the 
ensemble, which in turn could enhance or inhibit misfolding, or modulate cellular malfunction associated with 
αSyn overexpression.
In spite of the inherent challenges, we previously identified potential small molecule binders to αSyn using an 
in silico screen. We showed that one of these compounds, 484228, displayed protective activity in reversing αSyn 
over-expression mediated neurodegeneration and impairment of phagocytosis without impact on aggregation 
of the recombinant protein20, thus supporting the notion that small molecules can target an IDP such as αSyn 
and in doing so modulate cellular malfunctions independent of inhibitory effects on aggregation in solution. 
Encouraged by the success of the in silico screen, we embarked on biophysical screens to identify compounds that 
bind to IDPs using a surface plasmon resonance (SPR) based assay in which compounds are tethered to the chip 
(high-throughput chemical microarray surface plasmon resonance imaging, HT-CM-SPR)21. HT-CM-SPR has 
been successfully applied for the identification of small molecule binders to globular proteins, providing starting 
hits for drug discovery21,22. Remarkably, we successfully used HT-CM-SPR to identify small molecules retarding 
the aggregation of tau protein, another IDP that misfolds in neurodegenerative diseases23.
Here we apply the HT-CM-SPR screening technology to αSyn, and in addition to searching for 
aggregation-blocking compounds, as we did in the tau screen, we search for compounds correcting additional 
disease-relevant malfunctions of αSyn. We report here the identification of novel compounds that interact with 
native αSyn. A subset of these compounds can rescue αSyn dysfunction by reducing αSyn aggregation. Others 
can restore vesicular dynamics impaired by αSyn overexpression, as reflected in phagocytic capacity, while a 
distinct compound can block αSyn cell-to-cell transmission, without direct impact on aggregation. The iden-
tification of small molecules reversing diverse malfunctions of αSyn indicates that differing conformations and 
associated malfunctions of the protein may be targeted by small molecule ligands.
Results
Identification of small molecule binders of αSyn by high-throughput chemical microarray sur-
face plasmon resonance imaging (HT-CM-SPR) screening. Monomeric αSyn was screened against a 
library of small molecules containing 91,000 lead-like and 23,000 fragment compounds immobilized on microar-
rays to identify small molecules binding to the protein using surface plasmon resonance (SPR) imaging (HT-CM-
SPR)21,22 (Fig. 1a). An advantage of this chemical microarray paradigm is that αSyn is maintained in a soluble, 
monomeric, and label-free state enabling it to assume its heterogeneous conformational ensemble during screen-
ing. Moreover, the SPR-based detection is highly sensitive, which allows for identifying weak binding events22.
The monomeric nature of the αSyn was verified by dynamic light scattering (DLS), its native monomeric 
conformation ensemble by Nuclear Magnetic Resonance (NMR) and its purity by electrophoretic analyses 
(Supplementary Figs S1–S3). NMR H1-N15 HSQC analyses compared the commercially generated αSyn protein 
used in the screen to that prepared in-house using standard protocols for preparation of monomeric ensembles of 
αSyn and they showed identical spectra (Supplementary Fig. S2). To verify the monomeric nature of αSyn in the 
screen, DLS analyses were performed on αSyn preparations under screening conditions and in parallel for each 
library screening experiment. αSyn stock solutions were shown to be free of aggregates with negligible (<0.1%,) 
amounts of oligomers present. αSyn in screening buffer subjected to three-hour long incubations, the maximum 
amount of time used during screening, remained monomeric (Supplementary Fig. S3). In addition, there was no 
evidence of increasing SPR signal during the three-hour screening, as would have been seen had the αSyn been 
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oligomerizing on the microchip. Thus, the detected SPR signal reflects the interactions between monomeric αSyn 
and the immobilized library.
Microarrays were incubated with αSyn under optimized conditions, imaged and subjected to hit selection as 
described in the Supplementary Information. Briefly, chips were incubated with monomeric αSyn under condi-
tions optimizing signal and shown to maintain αSyn in its monomeric state (Supplementary Fig. S3). Figure 1b 
shows representative examples of αSyn SPR fingerprint analyses for two individual microarrays selected from the 
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Figure 1. HT-CM-SPR Screening of αSyn. (a) The HT-CM-SPR process: Monomeric αSyn analyte floats over 
the array surface in screening buffer to allow binding events to occur. SPR imaging enables the detection of 
binding events. (b) SPR Test Screening Results: The upper two panels show images of color coded SPR signals 
obtained during HT-CM-SPR of αSyn under optimized screening conditions against individual representative 
microarrays comprised of (1) a fragment microarray containing 3,070 fragments (out of 23,000 fragments 
present in the entire screened NovAliX chemical microarray library) spotted in triplicate along a diagonal 
and (2) a lead-like microarray of 9,216 lead-like compounds (out of 91,000 lead-like compounds present in 
the entire screened NovAliX chemical microarray library) individually spotted. The lead-like compounds are 
derived from combinatorial synthesis approaches with each row and column on the microarrays consisting 
of a common fragment in combination with 96 other diversities. In these fingerprint representations of the 
microarrays each spot is representative of a separate small molecule tethered to the array with the location on 
the chip reflected by the location on the fingerprint and the color representing the intensity of signal for that 
spot (color ranging from low shifts (blue) to high (red) signals). The lower panels 3 and 4 show reproducibility 
of duplicate screening experiments for chemical microarrays shown in panels 1 and 2. The reproducibility of 
these subsets of compounds is representative of results obtained for the entire NovAliX chemical microarray 
library with (3) triplicates of 3,070 fragments and for (4) individual 9,216 lead-like compounds immobilized. In 
these scatter plots, each spot compares the signal strength measured for the microarray samples in each of the 
independent array experiments with signals from one replicate experiment indicated on the Y-axis and that of 
the other experiment represented on the X-axis.
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13 arrays that comprise the library. Shown are examples of a microarray containing fragments (panels 1 and 3) 
and another microarray containing lead-like compounds (panels 2 and 4). Panels 1 and 2 show imaging analyses 
of the microarrays with each spot reflecting the position of a tethered small molecule sample on the array and 
the color of that spot reflecting the signal upon incubation with αSyn. On chips containing lead-like compounds 
based on combinatorial synthesis approaches, related library compounds are arrayed in rows and columns, with 
one unique copy per compound species present per physical microarray. Hence hit series with multiple members 
interacting with αSyn generated array patterns of colored lines as shown in Fig. 1b panel 2. Such patterns can 
be used to identify hit series with multiple related compounds interacting with the target protein. Some chips 
also contain many singleton compounds for diversity in the library, so these generated hit patterns of single 
colored spots. The low molecular weight fragment library compounds, in contrast, were spotted in triplicates and 
therefore triplicate signals of αSyn interacting fragment hit compounds can be observed (Fig. 1b panel 1). Each 
array was assayed in duplicate during the screen. Figure 1b panels 3 and 4 show scattergrams that illustrate the 
reproducibility of the raw SPR signals for each spotted sample in two independent repetitions for a representative 
of each type of microarray (the same representative microarrays shown in panels 1 and 2). The reproducibility of 
these subsets of compounds on the chosen microarrays is representative of results obtained for the entire library. 
Averaged SPR signals from replicate samples were filtered to remove outliers and JARRAY, NovAliX’s proprietary 
software routine, guided hit selection.
The screen identified 563 immobilized hit compounds interacting with αSyn, corresponding to a hit rate of 
0.49%. The signal strength and hit rate generally were lower than that of previously screened globular proteins, 
but comparable to those obtained for our screen on the tau protein with HT-CM-SPR23. While for globular pro-
teins of similar molecular weight to that of αSyn, signal to noise ratios of more than 10 were regularly obtained, 
for αSyn the signal to noise ratios ranged between 2 and 5. Nevertheless, as for the tau screen, hit compounds 
could be determined. Overall, hits included compounds which could be grouped into various compound classes 
and a number of structurally independent singleton compounds. We selected 152 representative hits out of the 
initial set of 563, based on parameters such as physicochemical properties, molecular weight, SPR signal strength, 
structural diversity, chemical tractability and overall attractiveness for drug development. This selected set con-
tains structurally diverse and different lead-like and fragment-like compounds. Interestingly, a high number of 
positively charged and structurally different amines were identified. The molecular physicochemical properties 
indicate tractability for drug development of this compound set (Tables 1 and S1). For further analysis of unteth-
ered hit compounds in follow-up assays, a subset of 65 compounds was selected for synthesis. This subset, the 
properties of which can also be found in Table 1, was chosen to cover chemical space of each structural class 
identified from the screen including singletons. All 65 compounds were synthesized devoid of the chemtag linker 
moiety, which was replaced with appropriate atoms/groups.
Multiple hit compounds inhibit αSyn fibril and oligomer formation and one blocks cellular neu-
rotoxicity. Misfolding of αSyn can result in the formation of toxic oligomers and amyloid fibrils24. Binding of 
small molecules to αSyn could block or enhance the transition of αSyn to β-sheet rich soluble oligomers and or 
fibrils depending on what conformation or sites are bound. We therefore screened the synthesized hit compounds 
in an αSyn aggregation assay, in which the fibril formation of the protein is monitored by Thioflavin T (ThT) fluo-
rescence. Two compounds (576755 and 582032) are shown here which inhibit the fibrillization of αSyn (Fig. 2a). 
Shown in Fig. 2a for these compounds are examples of three separate experiments with the average of quadru-
plicate samples at each time point. Statistical analyses as described in Supplementary Information were used to 
determine significance of differences between compound and DMSO control. For the experiments summarized 
in Fig. 2a a significant difference from DMSO control was found for compound 576755 in 3 out of 3 experiments, 
152 linked array hits 65 compounds resynthesized
Min Max Mean Median Min Max Mean Median
MW (Da) 150 499 340 338 151 488 325 336
ClogP −1.07 4.86 2.57 2.88 −1.34 5.03 2.36 2.45
#ACCEPTORS 1 6 3.36 3 1 5 3.11 3
#DONORS 1 6 2.72 3 1 5 2.6 3
#ROTBONDS 1 10 5.97 6 1 10 5.46 5
#RINGCOUNT 1 5 2.66 3 1 4 2.54 2
HAC 11 35 24.21 24 11 34 23.22 24
TPSA 21 157 83.27 84 21 137 80.87 79
Table 1. Physico-chemical properties of selected hit compounds. Analysis of the physico-chemical properties 
for the 152 representative hit compounds selected from the initial pool of 563 hits identified by the HT-CM-
SPR screen of monomeric αSyn, as well as for the 65 resynthesized compounds. For immobilization to the 
chip surface all library compounds were tethered to the chip via a linker group R. In order to calculate the 
ClogP, H-bond acceptor count, H-bond donor count, the count of rotatable bonds and TPSA (topological polar 
surface area) for the 152 array hits, this R-group was virtually replaced by a carbon. For the calculation of the 
molecular weight (MW) and Heavy Atom Count (HAC) the R group was replaced by a hydrogen atom. For the 
65 resynthesized compounds, the linker group R at the attachment point at the compound was synthetically 
replaced by other groups such as methyl groups, which are included in the calculation of all properties.
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Figure 2. Multiple HT-CM-SPR screening hit compounds block αSyn misfolding. (a) The impact of 
compounds on αSyn fibrillization activity, monitored by thioflavin T fluorescence, is shown. Examples are 
shown of three independent experiments for compounds tested at 300 μM in the αSyn fibrillization assay along 
with 0.5% DMSO control. Boxed numbers indicate the ratio of experiments demonstrating significant impact. 
Statistical analyses, (see Supplementary Information) indicate significant differences (p-value < 0.05) from 
DMSO for 576755 in 3 out of the 3 shown experiments, and for 582032 in 2 out of 3 experiments. Compound 
573434 has no impact on αSyn fibrillization in a biochemical assay. (b) Anti-fibrillization activity of compound 
576755 at 300 μM is demonstrated in both the standard (left) and seeded-aggregation (right) assays in which 
αSyn protofibrils are added at the initiation of the assay. (c) A dose response for compound 576755 in the 
fibrillization assay shows activity as low as 25 μM. For all fibrillization figures each data point represents the 
mean ± SEM of quadruplicate wells. (d) Dose response of anti-oligomerization activity of three compounds 
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and for compound 582032 in 2 out of 3 experiments with a trend to inhibition in the third experiment. Addition 
of compounds to αSyn monomer and ThT in the presence of preformed αSyn fibrils (Fig. 2b, seeded fibrilli-
zation) demonstrates that compound 576755 blocks fibril growth in this rapid and robust paradigm showing 
activity as early as 2 hours in the incubation (Fig. 2b, right panel). The slower time-course of the traditional 
(non-seeded) fibrillization assay run in parallel is shown in Fig. 2a. Compound 576755 shows near half-maximal 
anti-fibrillization activity at a substoichiometric concentration of 25 μM (Fig. 2c) in the traditional fibrillization 
assay, in which αSyn is incubated at 70 μM.
Compelling evidence supports pre-fibrillar αSyn oligomers as the pathogenic species in disease. αSyn oli-
gomers are directly toxic to cells25, and mutations enhancing αSyn oligomer formation increase αSyn toxicity26,27. 
We therefore screened our compound set for impact on biochemical and cellular αSyn oligomerization. Two 
novel biochemical assays were developed for αSyn oligomerization based on either bioluminescent complemen-
tation of Gaussia luciferase (GLuc) split tags or on FRET of small molecule tags (see Supplementary Fig. S5 and 
Supplementary Information). The oligomerization assays we report here are sensitive, quantitative and repro-
ducible assays of early αSyn misfolding and the bioluminescent assay in particular has a good dynamic range 
(Supplementary Fig. S5). The 65 synthesized hit compounds were tested in the biochemical bioluminescent com-
plementation assay at 100 μM and three active compounds were identified (Fig. 2e), including the two com-
pounds active in the fibrillization assay (Fig. 2d: 576755, IC50 of 10.5 μM, and 582032, IC50 of 290 μM) and an 
additional compound (573437, IC50 of 104 μM). The activities of all three compounds were verified in the FRET 
based αSyn biochemical oligomerization assay (Fig. 2f), demonstrating that the compound action was directed 
at αSyn and not the luciferase tags. The development of the novel oligomerization assays, which are much less 
variable than fibrillization assays, allowed us to identify the additional compound 573437 which most likely due 
to the variability of the fibrillization assay did not reach significance during the fibrillization testing.
Maximal concentrations of compounds not showing toxicity were tested in H4 neuroglioma cells for impact 
on αSyn cellular oligomerization using a bioluminescent protein-fragment complementation assay28. The only 
compound that reproducibly reduced cellular oligomers was 576755 (Fig. 3a). Western controls show no signif-
icant change of cellular αSyn protein levels by 576755 (Fig. 3b, a trend to increase is seen). To test the effects of 
576755 on αSyn-induced neurotoxicity, we used a primary midbrain culture model of PD29. As a control, we first 
established that there is no detectable toxic effect on primary dopaminergic neurons exposed to 60 μM 576755 
alone (Fig. 3c). Transduction of the primary cultures with an adenovirus encoding A53T αSyn, a PD-linked 
genetic mutant found to form toxic oligomeric species more readily than the wild type protein5,30, results in a 
30–40% reduction in the number of TH-immunoreactive neurons (Fig. 3d). In contrast, transduction with a virus 
encoding the control protein LacZ has no effect on neuron viability31. Treatment of the primary midbrain culture 
with 576755 at 60 μM, suppressed A53T αSyn neurotoxicity, and a trend towards a similar inhibitory effect was 
observed for cultures treated with the compound at 10 µM (Fig. 3d).
Multiple hit compounds reverse αSyn mediated inhibition of vesicular dynamics. Elevated 
αSyn can interfere with the creation, localization, and/or maintenance of vesicle pools32,33. We have demon-
strated that αSyn overexpression impairs phagocytosis in H4 neuroglioma cells, in primary microglia isolated 
from αSyn transgenic animals overexpressing αSyn and in cells from human PD patients by blocking recruitment 
of vesicular components necessary to support a phagocytic response34. We further reported that an αSyn binding 
compound derived from an in silico screen, 484228, restored normal phagocytosis in the face of ongoing αSyn 
overexpression20. We thus tested whether the αSyn binding hit compounds found here could protect against 
this αSyn over-expression induced dysfunction. The synthesized hit compounds were screened first for cellular 
toxicity at ranges from 1 μM to 100 μM. 53 compounds, showing no toxicity at 1 μM, in the absence of serum 
were subjected to further screening for their impact on phagocytosis in H4-neuroglioma cells overexpressing 
αSyn20,34 at two concentrations below that for which toxicity was seen. Seven compounds showed robust activity 
in reversing αSyn mediated inhibition of phagocytosis in H4-neurogloma cells in the initial screen. Five of these 
compounds were retested at 10 and 1 μM and 100 nM concentrations (Fig. 4a). All compounds showed complete 
reversal at 1 µM and two compounds (573418, 573419) showed complete reversal at 100 nM (Fig. 4a). Western 
analyses demonstrate that none of these compounds alters αSyn protein levels (Fig. 4b) and none of these com-
pounds impaired αSyn oligomerization (Fig. 2e).
One hit compound blocks αSyn cellular transmission without apparent impact on misfold-
ing. Lower-order αSyn oligomeric species and fibrils propagate their misfolded structure and transmit from 
cell-to-cell in a prion-like manner35–37. We therefore tested selected compounds in a cellular model of αSyn trans-
mission38,39. Figure 5 shows that compound 573434 retards αSyn transmission both in B103 rat neuroblastoma 
cells using a co-culture paradigm (at the Gladstone Institutes; Fig. 5a) and as executed at a different institution in 
primary neurons using a separate chamber culture paradigm (at UCSD; Fig. 5b,d) with activity at 10 μM 573434. 
573434 has no observed impact on αSyn fibrillization nor oligomerization (Fig. 2a,e) and does not impact αSyn 
are shown in a split Gaussia luciferase (GLuc) complementation assay executed as described in Methods. 
GLuc units are in arbitrary light units. The top panel shows the time course of inhibition by 576755 at multiple 
doses and the bottom panel shows the dose response and IC50s of all three active compounds at t = 24 hours. 
(e) The impact on oligomerization for all compounds discussed in this manuscript are shown. GLuc units are 
normalized to the mean of DMSO control. Means ± SD. are shown. (f) The anti-oligomerization activities of the 
three compounds identified in panel (d) are validated in a FRET based αSyn oligomerization assay executed as 
described in Methods. Compound structures are also shown in Supplementary Fig. S4.
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levels in the donor cells as measured by quantitative immunohistochemistry (Fig. 5c) and by Western analyses 
(Supplementary Fig. S6). Furthermore 573434 does not impact the secretion of αSyn from cells as determined by 
Western analyses (Fig. 5e). Thus, the mechanism of action of 573434 is not due to direct action on αSyn misfold-
ing, nor on expression or excretion of αSyn.
Discussion
In a prior study we reported on a novel strategy to target the monomeric intrinsically disordered ensemble of 
αSyn by using a structure-based computational docking screening approach to identify small molecules predicted 
to bind to monomeric αSyn, and then testing their impact in diverse αSyn mediated biochemical and cellular 
assays. An advantage of this approach is its potential to identify compounds that have a variety of effects related to 
αSyn malfunction or misfolding. This effort identified one compound, 484228, which reversed the impairment of 
phagocytosis, dopaminergic neuronal loss and neurite retraction caused by overexpression of αSyn20.
In order to expand upon this strategy, we applied a biophysical-based binding screen that detected the inter-
action between a small molecule and native monomeric αSyn, using SPR technology, an approach we have 
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Figure 3. Cellular activities of anti-aggregation compound 576755. (a) 576755 reduces αSyn oligomerization 
in H4 cells as measured by complementation of αSyn proteins with split luciferase tags executed as described 
in methods. Trace firefly luciferase co-transfected provides a normalization measure for transfection efficiency. 
0.3% DMSO is present in all samples. Data are plotted as means +/− SD. Shown are representative results 
from 3 independent experiments. A reduction in cellular oligomerization by 576755 was determined by one-
way ANOVA with Dunnett’s post-test. (b) 576755 does not reduce on αSyn levels in H4 cells as determined 
by Western analyses (trend towards small increase seen). (Right) representative Western from one experiment 
of a merged image detecting actin and αSyn from H4 cells transiently transfected with vector control or αSyn 
containing N or C terminal split luciferase tags (SynGN + SynGC) and treated with 0.3 percent DMSO or 
150 µM 576755. The two αSyn bands correspond to different tags. Entire length of blot shown. Outline of 
full blot shown by black lines. (Left) αSyn was quantitated in 3 separate biological replicates. Samples were 
normalized to cells transfected with αSyn without drug treatment to allow comparisons between blots. There is 
no significant difference in αSyn levels in 576755 treated vs. untreated cells (100) as determined by one sample 
t test. Data are plotted as mean ± SD. (c) 576755 is not toxic and (d) alleviates loss of dopaminergic neurons 
induced by the A53T mutant of αSyn. Primary rat embryonic midbrain cultures were non-transduced or 
transduced with adenovirus encoding A53T αSyn (+Ad SynA53T), in the absence or presence of 576755. The 
cells were then stained immunocytochemically for MAP2 and TH. Preferential dopaminergic cell death was 
assessed by evaluating the percentage of MAP2-positive cells that also stained positive for TH. Data are plotted 
as the mean ± SEM. n = 2–3 for the neuron toxicity analysis and n = 5 for the reversal of αSyn toxicity. Shown 
are representative results from 5 independent experiments. Statistics used a one-way ANOVA with Tukey post-
test after square root transformation of the data. *p < 0.05 where shown. ***p < 0.001. **** p < 0.0001. ns is 
not significant.
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successfully used to identify anti-aggregation compounds for the tau protein23. The current screen identified over 
500 hundred small molecules interacting with αSyn. We further showed that some of these compounds could 
beneficially impact αSyn malfunctions observed not only in aggregation assays, as we had found for the previous 
tau protein screen23, but also in multiple cellular malfunction assays. Our anti aggregation compound 576755 
blocked cellular αSyn oligomer formation and protected dopaminergic neurons against αSyn toxicity. We found 
compounds similar to our reported 48422820 that reversed the impairment of phagocytosis by αSyn, and we also 
found a different compound that blocks cell-to-cell transmission of αSyn. Further studies will be needed to estab-
lish whether these compounds interact with the different conformations of monomeric αSyn and/or higher-order 
assemblies. Overall, however, as we had anticipated, an expanded screen for compounds binding to monomeric 
αSyn yielded a variety of novel classes of compounds having different effects on αSyn mediated pathological 
processes providing a rich starting point for drug-discovery.
There is ample evidence that links αSyn misfolding and aggregation to the onset and progression of PD40. It is 
still unclear, however, which conformations of misfolded αSyn contribute most to pathogenicity. Prior screens for 
compounds modulating αSyn aggregation have relied largely on screening in fibrillization assays, and many have 
yielded compounds that block aggregation in a non-specific manner mediated through polymeric self-stacked 
forms of the compounds41,42 or via reactive quinone formation43 which complicates translation into effective 
Figure 4. Multiple HT-CM-SPR screening hit compounds alleviate αSyn mediated inhibition of phagocytosis 
in H4-Neuroglioma cells. H4 neuroglioma cells over-expressing αSyn from a tetracycline-inducible promoter 
were cultured for 24 hours with compound in the absence or presence of αSyn induced by tetracycline. After 
24 hours of induction cells were (a) fed 4 micron beads for 90 minutes and a phagocytic index was measured by 
quantitating the amounts of engulfed beads on an imaging reader or (b) analyzed by Western blot to determine 
αSyn levels. (a) The phagocytic capacity was calculated by normalizing the indicated samples to the phagocytic 
capacity of un-induced cells not overexpressing αSyn (Tet off). Each point corresponds to a separate experiment 
denoting the average of 6 well replicates. Means ± SD for the combined multiple experimental averages are 
shown. Control compound is 484228, identified in a prior in silico screen20. n = 2 or 3 different experiments 
as shown. Significance was determined by ANOVA with Dunnet’s correction. *p < 0.05, ***p < 0.001, 
****p < 0.0001. ns is not significant. (b) Cells were untreated or treated with tetracycline to induce αSyn and 
treated with DMSO or compounds and analyzed by Western blot for actin and αSyn levels. Left: Representative 
Western blots of merged actin and αSyn signals of individual wells treated with DMSO or compounds. Image 
cut as shown to remove irrelevant samples. Entire length of blot shown. Outline of full blot shown by black 
lines. Right: Westerns from multiple replicates were quantitated and the αSyn band intensity was normalized 
to that of actin. Each data point is a separate well. No compounds showed significant impact on αSyn levels. 
Compound structures are also shown in Supplementary Fig. S4.
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drugs. Although our most potent anti-aggregation compound, 576755, has quinone potential, two additional 
misfolding blocking compounds without this liability were found in this screen using novel oligomerization 
assays. The biochemical bioluminescent protein complementation αSyn oligomerization assay, in particular, is a 
highly useful and novel assay in that it is amenable to high-throughput screening and does not rely on shaking or 
detergents to accelerate αSyn misfolding as is the case for a recently published αSyn high-throughput oligomer-
ization assay44. The ability to identify anti-aggregation compounds through a fundamentally different screening 
paradigm - that of SPR-based screening using monomeric αSyn - allowed us to obtain alternative compounds 
inhibiting aggregation. This will potentially expand our repertoire of anti-aggregation compounds to include 
compounds of possibly novel and druggable mechanisms.
The role of αSyn in modulating vesicle dynamics in cells is well established33,45–48, and there are links between 
αSyn toxicity and vesicular dysregulation33. We have reported that phagocytosis, which involves both mobilization 
and extrusion of vesicles, is impaired by αSyn over-expression in cultured cells and in vivo in transgenic mice as well 
as in cells from Parkinson’s patients34 suggesting that this dysfunction is a relevant target for therapeutic intervention 
in PD. Our experience using 484228 as a control compound in scores of assays at high doses is that it never restored 
phagocytosis inhibited by αSyn overexpression beyond 80 percent of that in cells with endogenous αSyn levels. 
The compounds reported herein restore phagocytic capacity to 100 percent of control and thus are likely to act via 
mechanisms distinct from that of 484228. Thus, the identification of multiple drug-like compounds with different 
scaffolds reversing αSyn impairment of phagocytosis expands upon our earlier results with compound 484228.
Figure 5. One HT-CM-SPR screening hit compound blocks cell-to-cell transmission of αSyn. (a) The impact 
of 573434 on transmission was tested on co-cultured donor and recipient B103 neuroblastoma cells and mean 
percentage of receiving cells with αSyn is shown. The same data are shown separating all compound doses (left) 
or combining 100 and 150 µM (right). 3 coverslips/well per group, 10–15 pictures per coverslip, and 43–168 cell 
total per group were analyzed. Combined 100 and 150 µM drug samples give statistically significant differences 
from untreated by unpaired t test (n = 3). (b) Donor and acceptor primary neurons were cultured in separate 
chambers of a Transwell and αSyn in acceptor cells was measured after treatment with 573434 or 576755. Vector 
control is lentiviral vector not expressing αSyn. 10 and 100 µM 573434 retarded transmission whereas 576755 
had no impact as determined by ANOVA with Dunnett’s correction. (c) Total αSyn levels were determined from 
the fluorescent intensity from αSyn antibody (arbitrary fluorescence units, AFU) in the images used in panel 
(a). 3 coverslips per group, 8–11 pictures per coverslip, and 24–54 cell total per group were analyzed. 573434 
does not impact overall expression of αSyn as determined by unpaired t test. (d) Representative images of αSyn 
transmission in primary neurons treated with 573434 and 576755. (e) Cells and media produced by B103 cells 
infected with control or αSyn-lentivirus and treated with DMSO or 150 μM 573434 were analyzed by Western 
blot for actin and αSyn levels. Left: Western blot of both actin and αSyn proteins of duplicate wells. Image cut 
as shown to remove irrelevant samples. Entire length of blot shown. Outline of full blot shown by black lines. 
Right: the ratio of αSyn in the media to αSyn in the cell was quantitated from three separate experiments 
with duplicate wells (n = 6). αSyn levels in cells and media were normalized to actin levels in cells of that well 
and then further normalized to control (DMSO) sample on the same gel to allow for comparison between 
experiments. 573434 has no impact on the amount of αSyn secreted into the media. For all figures drug treated 
and control cells are in equivalent levels of DMSO (0.15 to 0.3%). Each symbol represents a singe coverslip in a 
unique well. Mean ± SD. *p < 0.05, ***p < 0.001, ****p < 0.0001, ns–not significant. Compound structure is 
also shown in Supplementary Fig. S4.
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A central role of transmission and propagation of misfolded αSyn in disease is widely accepted37. Although 
antibodies to αSyn are being tested in the clinic to block pathogenic spreading49, small molecules targeting IDP 
spread are limited to aggregation inhibitors and to a single pharmacological chaperone50. The anti-fibrillization 
compound 576755 did not impact transmission, despite its ability to reduce cellular oligomers. This could be due 
to differing drug sensitivities in the cells used in these assays. Nevertheless, we have identified a different small 
molecule, 573434, which blocks the transmission of αSyn from one neuronal cell to another. This compound does 
not change overall αSyn levels, ruling out a non-specific impact on the vector. It furthermore does not impact the 
overall levels of αSyn secreted from the cells. In biochemical assays it impacts neither αSyn oligomerization nor 
fibrillization indicating a novel mode of action for this molecule. There remain a number of possible mechanisms 
including (1) reduction of overall uptake of αSyn into receiving cells or (2) reduction of levels of a subpopulation 
of αSyn that is preferentially taken up in receiving cells. For example, Danzer and colleagues have shown that 
only the fraction of extracellular αSyn that is packaged into exosomes in the media is transmitted into receiving 
cells51,52. Levels of this specific αSyn pool could be reduced by 573434. Further studies are needed to elucidate an 
exact mechanism of action for this compound.
The high-throughput approach described here may also be applied to other IDPs. Indeed, in a related study, we 
applied HT-CM-SPR screening for small molecules interacting with monomeric full-length tau, which resulted 
in the discovery of a variety of compounds which were able to reduce the aggregation of tau in vitro and in a cell 
model23. Hence, these studies add to the accumulating evidence that small molecules can bind to IDPs, such as 
αSyn20, tau23,53 and the Aβ peptide54, despite their overall lack of persistent 3D structures.
In conclusion, these results support the notion that the dynamic monomeric solution state of αSyn can be 
successfully targeted by drug-like small molecules to reverse PD relevant dysfunctions. Our identification of small 
molecules impacting multiple types of αSyn malfunction demonstrates that targeting αSyn with screens employ-
ing ensembles of predominantly monomeric protein offers a rich and effective opportunity for drug discovery. We 
thus anticipate that this approach will be useful for the development of small molecule therapeutic candidates for 
Parkinson’s disease and other diseases associated with IDP misfolding.
Methods
Additional details are in Supplementary information.
SpR screening of monomeric αSyn. The binding of αSyn was evaluated on a set of 96 control ligands of 
defined physical chemical properties in order to optimize buffer composition, ligand surface density and αSyn 
concentration. Minimum background and maximal total signal were obtained using 900 nM αSyn protein in 
25 mM Tris and 100 mM NaCl, pH 7.4. αSyn at 10x that of screen concentration was predominantly monomeric 
as measured by DLS (>99.9%, see Supplementary Information). Freshly diluted αSyn in screening buffer was 
centrifuged through a 100kD cut-off filter, before incubation at room temperature on the arrays for up to 3 hours. 
Duplicate chips were run, with unique samples for the lead-like library and triplicate samples for the fragment 
library. Multiplicate SPR signals were averaged per compound. Compounds with standard deviation more than 
0.5, or for which the purity before spotting or the saturation per spot was less than 80 percent were discarded.
Fibrillization assays. Prior to each aggregation assay, purified αSyn at 5 mg/mL was treated with 6M gua-
nidine and dialyzed 36 hours in a 3500 MW cutoff Slide-A-lyzer with three changes of 20 mM sodium phosphate 
and 100 mM NaCl pH 7.4 buffer. αSyn was centrifuged at 130,000 g for 40 minutes in a Beckman Ultracentrifuge 
to remove seeding species and supernatant used for assays. For initial testing, compound was diluted to appro-
priate concentrations in 0.5% DMSO and controls contained equivalent DMSO concentrations. Assay samples 
contained 20 μM Thioflavin T, filtered through a 0.45 μm Acrodisc filter prior to each assay, 70 μM αSyn in 20 mM 
sodium phosphate and 100 mM NaCl pH 7.4. One teflon bead, (0.125″ PTFE, Grade 2 polished) was in each well 
of a 96 well black with clear bottom assay plate (Corning) in a total volume of 500 μL. The plate was sealed with 
Mylar and parafilm, placed at 37 °C in a Tecan F200Pro Plate Reader and shaken at an amplitude of 6 mm for 
120 hours continuously except for a brief time during reading of the plate. Thioflavin T fluorescence was detected 
by excitation at 440 nm and reading emissions at 485 nm each 60 minutes throughout the assay. To generate αSyn 
seeds for the seeding assays, αSyn at 10 mg/mL was incubated with stirring at 43 °C for 24 hours followed by 
exhaustive sonication. 1% (by mass) of seeds were added to the fibrillization assay. Samples were plated in quad-
ruplicate, and the replicates averaged for each experiment for plotted data. Data were analyzed in Excel using 
XL-fit sigmoidal model #600.
Biochemical αSyn oligomerization assays. For the split Gaussia luciferase (GLuc) oligomerization 
assay 10 μM each of αSyn-GLuc1 and αSyn-GLuc2 (see Supporting Information: N-terminal or C-terminal frag-
ment of GLuc fused to the C-terminus of αSyn) were incubated in a buffer containing 1 mM MgCl2, 1 mM ADP, 
50 mM Na3PO4, 0.02% NaN3 and 1 mM DTT at pH 7.4 at 37 °C in a thermal cycler (BioRad DNA Engine PTC-
200). In some cases, when specified, the samples were incubated with shaking in an incubator at 37 °C. At 0, 6, 
12, and 24 hours of incubation GLuc activity was quantified using the BioLux Gaussia Luciferase Assay Kit (NEB) 
according to the manufacturer’s instructions with luminescent detection on a SpectraMax M5 Microplate Reader 
(Molecular Devices) using a 5 minute delay after the addition of substrate and 3 seconds of integration time.
For the FRET oligomerization assay,10 μM each of αSyn-Q-(Position#)C-Cy3 (donor) and αSyn-Q-(Posi-
tion#)C-Cy5 (acceptor) in PBS (pH 7.4) were dispensed into black/clear bottom 384-well plates (Greiner) using a 
Mantis liquid handler (Formulatrix). The plate was sealed with AbsorbMax film (Sigma-Aldrich) and incubated at 
37 °C. The FRET between donor and acceptor was measured on a SpectraMax M5 Microplate Reader (Molecular 
Devices). An excitation wavelength of 525 nm for αSyn-Cy3 (donor), and emission wavelengths of 570 nm and 
670 nm for αSyn-Cy3 (donor) and αSyn-Cy5 (acceptor) respectively were used. The plate reader PTM sensitivity 
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was set to medium and assays executed without mixing. The signals were read at 10 minute intervals for 99 hours 
at 37 °C. Efficiency of FRET was calculated as follows: EFRET = IAcceptor/IDonor, in which IAcceptor is acceptor emission 
intensity, IDonor is donor emission intensity.
cellular αSyn oligomerization assay. H4 neuroglioma cells (HTB-148; ATCC) were passaged in 
DME containing 10% fetal calf serum (FCS). They were plated into 10 cm dishes at 7.5 × 105 cells per dish and 
the following day transfected with DNA and Fugene (Promega, Madison, WI) according to the manufactur-
er’s directions at a ratio of 3:1 with 7 μg each of Syn-Luc1 (S1) and Syn-Luc2 (S2) plasmids55 (also referred to 
as syn-hGLuc(1) and syn-hGLuc(2)55 respectively, kind gifts from Dr. Pamela McLean) and 3 μg of red firefly 
expressing plasmid (pCMV-Red firefly Luc, ThermoFisher, Waltham, MA) per dish. S1 and S2 plasmids express 
αSyn containing split Gaussia luciferase with either the N-terminal fragment (S1) or C-terminal fragment (S2) 
attached to the C-terminus of αSyn. After 24 hours, the DNA containing media was removed and cells were 
fed fresh DME media containing 10% FCS. The following day, cells were plated into polyD-Lysine coated clear 
bottom white well 96 well plates at 1.5 × 104 cells per well in Opti-MEM without phenol red with penicillin and 
streptomycin. After 4 hours cells are treated with drugs and incubated for 20 hours. Gaussia luciferase activity was 
measured in the dark 0.1 sec after injection of 100 μl/well of 40 mM coelenterazine, substrate (NanoLight, Pinetop, 
AZ) using a 2 second integration on a Veritas Microplate Luminometer (Promega, Madison, WI). The cells were 
subsequently assayed for red Firefly activity using the ONE-GloTM Luciferase Assay System kit (Promega, 
Madison, WI) on a Spectramax M5 (Molecular Devices, San Jose, CA) plate reader as a normalization measure. 
100 μl of media were also assayed for red firefly activity. The impact of compounds on H4 cell toxicity was assayed 
using the CytoTox-Glo kit (Promega, Madison, WI).
Phagocytosis assay. A human neuroglioma H4 cell-derived cell line stably over-expressing αSyn from a tetra-
cycline inducible promoter20 was grown in serum-free X-VIVO media (Lonza Group, Basel, Switzerland). Cells were 
seeded in 96-well plates at 100 K cells per well. The next day, compound was added along with 5 µg/ml tetracycline 
to induce αSyn overexpression. Cells were cultured overnight and the next day were fed 4 μM red fluorescent beads 
(In Vitrogen, Carlsbad, CA) for 90 minutes at a cell-to-bead ratio of 1:10. Plates were gently washed with 100 µl/well 
media twice, fixed and stained with HEMA3 (Thermo Fisher, Waltham, MA). Plates were dried overnight and read 
on an ArrayScan (Thermo Fisher, Waltham, MA). As the HEMA3 stain absorbs light, the internalized beads are less 
fluorescent than the outside beads. Tet/non-tet and 484228 samples were run on each plate.
Transmission assay. Lentivirus was made from the pLV-αSyn vector (LV-αSyn)56 expressing his tagged 
αSyn or control green fluorescent protein vector (LV-control) as described38. Titers were determined by P24 
protein ELISA (primary neuronal experiments) or quantitative PCR of genomic DNA using transducing units 
of virus expressing green fluorescent protein titrated on HEK293 cells serving as a normalizing control (rat B103 
experiments). Rat B103 neuroblastoma cells (from David Schubert, The Salk Institute) were grown in DMEM 
with 10% FBS at 37 °C in 10% CO2.. Cryopreserved mouse cortical neural stem cells (MCNS) (MilliporeSigma, 
Burlington, MA) were grown according to manufacturer recommendations. αSyn transmission between cells 
was done using the methods described38,39 in one of two ways: (1) B103 neuronal cells: donor B103 neuronal cells 
plated in 6 well plates at 250,000 cells per well were incubated with LV-αSyn or LV-control at an MOI of 20 for 
48 hours. B103 acceptor cells were labeled with the 595-Qtracker labeling kit (Life Technologies, Carlsbad, CA) 
according to the manufacturer’s protocol. Donor and acceptor cells were trypsinized and replated together in a 
12 well plate at 50,000 cells/well each on polyL coated coverslips. 4 hours post plating drugs were added. After 
48 hours of co-incubation cells were fixed in 4% paraformaldehyde (PFA). Coverslips were stained with Syn1 
antibody (BD Franklin Lakes, NJ) at a dilution of 1/500 and imaged on a Zeiss LSM 880 laser scanning confocal 
microscope and the percentage of receiving cells positive (cutoff of 10 standard deviations above negative control) 
for αSyn calculated by using ImageJ. Total αSyn levels were quantitated on the same images quantitating total 
fluorescence intensity from the Syn1 antibody using ImageJ. (2) MCNS neurons: Donor MCNS neurons were 
infected with LV-αSyn at a MOI of 20 for 48 hours, trypsinized and replated in 12 well cell culture inserts contain-
ing a 0.4 µm PET membrane (Thermo Fisher, Waltham, MA) at 50,000 cells/well. Acceptor MCNS were plated in 
the bottom chamber of the 12 well Transwell plate at 50,000 cells/well on a poly-l-lysine coated glass coverslip. The 
0.4 µm filter, allows passage of secreted proteins but restricts direct cellular contact. 4 hours post plating, drugs 
were added. Cells were co-incubated for 48 hours and fixed with PFA, followed by immunocytochemical analysis.
Statistical analysis methods. Methods for the analyses of compound activity in the synuclein fibrilliza-
tion assay are in Supplementary Information. Other statistical analyses were run using GraphPad Prism software 
as described. Multiple samples were compared using one-way ANOVA with Dunnett’s and an alpha of 0.05. In 
analyzing percentage cell viability data by ANOVA, square root transformations were carried out to conform to 
ANOVA assumptions, and Tukey’s post hoc test was used for multiple comparisons31. In cases where two samples 
were used t tests with an alpha of 0.05 were used. General practice significance nomenclature was used (0.1234 
(ns), 0.0332 (*), 0.0021 (**), 0.0002(***), <0.0001(****) unless otherwise indicated.
Compound analyses and handling. The 65 resynthesized compounds chosen for testing in functional 
assays were verified as the indicated structure and of sufficient purity by 1H-NMR and by liquid chromatography 
and mass spectrometry analyses (LC-MS). These 65 compounds were at least 85% pure, with most over 95% pure. 
The active compounds were all over 90% pure. Additional information including the LC-MS determined purity 
and 1H-NMR peaks for the 9 active compounds described herein are listed in Supplementary Information.
For all compound testing, controls are run in the equivalent amount of DMSO.
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Associated content. Supplementary Information includes detailed data with expanded description and 
expanded methods.
Data availability
The human neuroglioma H4 cell-derived cell line stably over-expressing αSyn from a tetracycline inducible 
promoter20 can be obtained after signing Material Transfer agreements with Imago Pharmaceuticals (bd@imago-
pharma.com) and Prothena Biosciences Inc (331 Oyster Point Boulevard South San Francisco, CA 94080, U.S.A. 
+1 650 837 8550). B103 neuroblastoma cells are available from Dr. David Schubert (schubert@salk.edu) with 
Material Transfer agreement from The Salk Institute (10010 N Torrey Pines Rd, La Jolla, CA 92037).
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